Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062128-afe67892_task_9aae8fc5",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "# Feasibility Assessment: NF-κB–Complement Cascade Hypotheses\n\n---\n\n## Hypothesis 1: Direct NF-κB Transcriptional Regulation of C1q Genes\n\n### Druggability\n**Moderate-High Technical Feasibility / Low Clinical Tractability**\n- **IKKβ inhibitors** (ML120B, BAY 11-7082) exist but lack selectivity; broad NF-κB suppression causes immunosuppression and hepatotoxicity\n- **REL-A/p65 inhibitors** are preclinical—no selective clinical-stage compounds exist\n- **BET bromodomain inhibitors** (JQ1) indirectly suppress NF-κB-dependent transcription but have pleiotropic effects\n- **Druggable target** exists but therapeutic index is narrow; systemically inhibiting NF-κB in microglia requires CNS-penetrant, cell-type-selective approaches not yet available\n\n### Biomarkers/Model Systems\n- **Biomarkers**: p65 nuclear translocation (flow cytometry of blood monocytes), C1QA/C1QB mRNA (qPCR), serum C1q protein (ELISA)\n- **Model systems**: Primary murine microglia (4% sevoflurane, 2h), human iPSC-derived microglia, ChIP-seq for p65 occupancy\n- **Gap**: Peripheral C1q does not reliably reflect brain complement activity; CSF sampling is invasive\n\n### Clinical Development Constraints\n- Demonstrating target engagement requires CNS penetration and microglial selectivity—currently intractable combination\n- Phase I would need extensive neurocognitive testing even with clean safety signals\n- Post-anesthesia neuroinflammation is acute and self-limited; trial design must capture narrow therapeutic window\n\n### Safety\n- NF-κB inhibition risks: impaired immune response to infection, impaired wound healing, hepatic toxicity, potential increase in neurodegeneration given NF-κB's neuroprotective roles\n- Chronic administration is contraindicated; acute periprocedural use would require single-dose safety database\n\n### Timeline/Cost\n| Milestone | Timeline | Cost |\n|-----------|----------|------|\n| Target validation + ChIP-seq | 12–18 months | $300–500K |\n| Lead optimization (selective IKKβ) | 24–36 months | $2–4M |\n| IND-enabling studies | 18–24 months | $3–5M |\n| Phase I safety (single-dose) | 12–18 months | $5–8M |\n\n**Overall Assessment**: Mechanistically plausible but drug development is high-risk due to pleiotropic NF-κB biology. The skeptic is correct that promoter κB sites ≠ functional regulation. Confidence should remain at **0.45–0.55** pending direct ChIP data.\n\n---\n\n## Hypothesis 2: Astrocyte IL-1β as Paracrine Mediator\n\n### Druggability\n**High Clinical Tractability**\n- **Anakinra** (IL-1RA): FDA-approved, safe, but poor CNS penetration (CSF:plasma ratio ~1:200)\n- **Canakinumab**: Monoclonal antibody; cannot cross BBB; not suitable for direct CNS effect\n- **LMW IL-1R antagonists** crossing BBB: Preclinical only (e.g., pyrin modulators)\n- **Astrocyte-selective IL-1β blockade**: Requires cell-type targeting not currently feasible in clinic\n\n### Biomarkers/Model Systems\n- **Biomarkers**: CSF IL-1β (ultra-sensitive Simoa), microglial IL-1R1 expression (CX3CR1+/IL-1R1+ flow), C1q protein in hippocampal tissue\n- **Model systems**: Astrocyte-microglia co-culture with transwell separation; GFAP-tdTomato mice for astrocyte-specific IL-1β measurement\n- **Advantage**: IL-1β is quantifiable in patient CSF; correlates with neuroinflammation severity\n\n### Clinical Development Constraints\n- IL-1β is one of several redundant inflammatory signals; blocking it may not reduce C1q sufficiently\n- BBB penetration of IL-1 inhibitors is",
  "tokens_used": "860",
  "persona_id": "persona-domain_expert"
}